St. Jude Medical upgraded to Outperform from Market Perform at Wells Fargo Wells Fargo upgraded St. Jude Medical citing the stabilizing the U.S. ICD market and reduced pipeline expectations. The firm raised its price target range for shares to $49-$50 from $40-$41.
News For STJ From The Last 14 Days
Check below for free stories on STJ the last two weeks.
St. Jude Medical study of EnligHTN shows sustained blood pressure reduction St. Jude Medical announced that the company's EnligHTN Multi-Electrode Renal Denervation System provides a safe, rapid and sustained reduction in blood pressure measurements after one year. Patients enrolled in the EnligHTN I trial had an average blood pressure of 176 / 96 mmHg and patients were drug-resistant, meaning their blood pressure could not be controlled through medication. At one year, patients treated with the EnligHTN Renal Denervation System experienced an average systolic blood pressure reduction of 27 mmHg points when measured in an office setting.
St. Jude Medical's 3-D vessel reconstruction system approved in Europe St. Jude Medical announced CE Mark approval of its Ilumien Optis PCI Optimization System, a new technology designed to provide physicians with a comprehensive disease assessment tool for treating patients with coronary artery disease. St. Jude Medical is the only company to provide these tools together in an integrated platform.
Subscribe for More Information